The value of monitoring human papillomavirus DNA results for Papanicolaou tests diagnosed as atypical squamous cells of undetermined significance: A College of American Pathologists Q-probes study of 68 institutions

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 10, 2007, Pages 1525-1531

  Tworek, Joseph A ^a   Jones, Bruce A ^b   Raab, Stephen ^c   Clary, Karen M ^d   Walsh, Molly K ^e  

^a ST JOSEPH MERCY HOSPITAL   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d ROCHESTER GENERAL HOSPITAL   (United States)

^e Molecular Pathology Division   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA DETERMINATION; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; PAPILLOMA VIRUS; PREVALENCE; PROBABILITY; QUALITY CONTROL; SQUAMOUS CELL; TEACHING HOSPITAL; VIRUS DIAGNOSIS;

DNA, VIRAL; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY, CLINICAL; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 35348933294     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Zur Hausen H, de Villiers EM. Human papillomaviruses. Annu Rev Microbiol. 1994;48:427-447.
2. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that HPV infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993;85:958-964.
3. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 1995;87:796-802.
4. Staler MH. Advances in cervical screening technology. Mod Pathol. 2000; 13:275-284.
5. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-2119.
6. Wright TC, Cox JT, Massad LS, et al. 2001; Consensus guidelines for the management of women with cervical cytological abnormalities JAMA. 2002;287: 2120-2129.
7. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guidelines for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342-362.
8. Confortini M, Biggeri A, Cariaggi MP, et al. Intralaboratory reproducibility in cervical cytology: results of the application of a 100-slideset. Acta Cytol. 1993; 37:49-54.
9. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL triage study. JAMA. 2001;285:1500-1505.
10. Solomon D, Schiffman M, Tarone R, for the ALTS Group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299.
11. Sherman ME, Schiffman MH, Lorincz AT, et al. Toward objective quality assurance in cervical cytopatholgy: correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. Am J Clin Pathol. 1994;102:182-187.
12. Zuna RE, Moore W, Dunn ST. HPV DNA testing of the residual sample of liquid-based Pap test: utility as a quality assurance monitor. Mod Pathol. 2001;14:147-151.
13. Riethmuller D, Gay C, Bertrand X, et al. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn Mol Pathol. 1999;8:157-164.
14. Clavel C, Bory J, Rihet S, et al. Comparative analysis of human papillomavirus detection by Hybrid Capture assay and routine cytologic screening to detect high-grade cervical lesions. Int J Cancer. 1998;75:525-528.
15. Hong IS, Marshalleck J, Williams RH, et al. Comparative analysis of a liquid-based Pap test and current HPV DNA assay of residual samples: a study of 608 cases. Acta Cytol. 2002;46:828-834.
16. The ALTS Group. Results of a randomized trail on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188:1383-1392.
17. Cox IT, Schiffman M, Solomon D, for the ALTS Group. Prosepctive followup suggests similar risk of subsequent CIN 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol. 2003;188:1406-1412.
18. Staler MH. Testing for human papillomavirus: data driven implications for cervical neoplasia management. Clin Lab Med. 2003;23:569-583.
19. Wachtel MS, Dahm PF. The ASCUS:SIL ratio and the reference laboratory pathologist. Cytopathology. 2003;14:249-256.
20. Wachtel MS, Boon ME, Korporaal H, et al. Human papillomavirus testing as a cytology gold standard: comparing Surinam with the Netherlands. Mod Pathol. 2005;18:349-353.
21. Ho GYF, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-428.
22. Melkert PWJ, Hopman E, van den Brule AJC, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer. 1993;53:919-923.